Conventional RECIST Might Underestimate Pembrolizumab Benefit for Melanoma

Share this content:
Conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab.
Conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab.

Because of atypical responses, conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab in approximately 15% of patients treated for melanoma, a study published in the Journal of Clinical Oncology has shown.1

For the study, researchers sought to evaluate atypical response patterns and the association between overall survival and best overall response measured per immune-related response criteria (irRC) and RECIST version 1.1 in patients with advanced melanoma treated with pembrolizumab.

Investigators analyzed data from the phase 1b KEYNOTE-001 study, which enrolled 655 patients with melanoma. Participants received pembrolizumab 2 or 10 mg/kg IV every 2 or 3 weeks.

Atypical responses were identified by using centrally assessed irRC data in patients with 28 or more weeks of imaging. Pseudoprogression was defined as an early 25% or greater increase in tumor burden at week 12 or any delayed assessment after week 12 that was not confirmed as progressive disease at next assessment. Investigators centrally assessed response per irRC and RECIST version 1.1.

Of the 655 patients, 327 had 28 or more weeks of imaging follow-up. Results showed that 7% of those experienced atypical responses, of which 5% had early pseudoprogression and 3% had delayed pseudoprogression.

Researchers found that of the 592 patients who survived 12 weeks or more, 14% experienced progressive disease per RECIST version 1.1 but nonprogressive disease per irRC.

Further, the study demonstrated that 2-year overall survival rates were 77.6% in patients with nonprogressive disease per both criteria, 37.5% in patients with progressive disease per RECIST version 1.1 but nonprogressive disease per irRC, and 17.3% in patients with progressive disease per both criteria.

RELATED: Total Nevus Counts Should Not Be Sole Reason for Determining Risk Status in Melanoma

The findings suggested that modified criteria that allow for treatment beyond initial disease progression per RECIST version 1.1 might prevent premature treatment discontinuation.

Reference

  1. Hodi FS, Hwu W-J, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab [published online ahead of print March 7, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.64.0391.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters